Skip to main content
Premium Trial:

Request an Annual Quote

KellBenz Licenses Antibodies from AdnaGen

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – KellBenx has licensed antibodies from AdnaGen which it will use to develop non-invasive prenatal diagnostics, AdnaGen's parent company, OncoVista Innovative Therapies said today.

Under the deal, KellBenz will use the antibodies to enrich fetal nucleated red blood cells "to perform chromosomal or genetic analysis to identify markers of potential disorders," OncoVista said in a statement.

FNRBCs have been identified in maternal blood as a possible source for monitoring and diagnosing maternal, fetal, and neonatal health and disease.

KellBenz has exclusive worldwide rights to commercialize AdnaGen's antibodies, called monoclonal antibodies with specificity for fetal erythroid cells, OncoVista said.

Financial terms were not disclosed.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.